Microbiome-immune Interactions: Implications for Disease and Therapy

Heung Lee^*
*Correspondence: Heung Lee, Department of Biological Sciences, University of Science and Technology, Daejeon, 34141, Republic of Korea, Email:

Introduction

In recent years, our understanding of the human microbiome and its intricate interplay with the immune system has revolutionized our perception of health and disease. The human body is host to trillions of microorganisms, collectively known as the microbiota, residing predominantly in the gastrointestinal tract but also colonizing other niches such as the skin, respiratory tract, and urogenital system. These microbial communities, comprising bacteria, viruses, fungi, and archaea, form a complex ecosystem that coevolves with the host throughout life. The microbiome, which refers to the genetic material of these microorganisms, plays a fundamental role in maintaining host homeostasis, influencing various physiological processes including metabolism, nutrient absorption, and immune system development. Importantly, the microbiome has emerged as a critical regulator of immune responses, contributing significantly to the education, maturation, and function of the immune system from birth through adulthood. The dynamic interaction between the microbiome and the immune system is bidirectional and multifaceted. On one hand, the microbiome shapes immune responses by providing essential signals that promote immune tolerance, regulate inflammation, and enhance antimicrobial defenses. Microbial-derived metabolites and structural components, known as microbial-associated molecular patterns (MAMPs), play key roles in these processes. On the other hand, the immune system exerts selective pressure on the microbiome, influencing its composition and diversity [1].

Understanding these microbiome-immune interactions has profound implications for human health and disease. Dysbiosis, or microbial imbalance, has been implicated in the pathogenesis of numerous disorders, including Inflammatory Bowel Diseases (IBD), allergic conditions, autoimmune diseases, metabolic disorders, and even neurological conditions. Conversely, therapeutic interventions that modulate the microbiome, such as probiotics, prebiotics, synbiotics, and Fecal Microbiota Transplantation (FMT), hold promise for treating these conditions by restoring microbial balance and optimizing immune function. This review aims to explore the intricate relationship between the microbiome and the immune system, elucidating its implications for disease pathogenesis and highlighting emerging therapeutic strategies. By unraveling the mechanisms underlying microbiome-immune interactions, we can pave the way for innovative approaches in personalized medicine that harness the microbiome to promote health and combat disease effectively. This introduction sets the stage by highlighting the significance of microbiome-immune interactions in human health and disease, emphasizing the bidirectional relationship between microbial communities and immune responses, and outlining the potential therapeutic implications of these interactions [2].

Description

The human microbiome, comprising trillions of microorganisms inhabiting various body sites, is increasingly recognized as a pivotal determinant of health and disease. This ecosystem of microbes, predominantly residing in the gut but also present in the skin, respiratory tract, and other mucosal surfaces, plays a crucial role in shaping host immune responses and maintaining immune homeostasis. The microbiome consists of diverse microbial communities, including bacteria, viruses, fungi, and archaea, each with unique roles and interactions within their respective niches. The composition and diversity of these microbial populations are influenced by various factors, such as diet, antibiotics, host genetics, and environmental exposures. Alterations in microbiome composition, known as dysbiosis, can disrupt immune regulation and predispose individuals to a range of diseases. The interaction between the microbiome and the immune system is bidirectional and multifaceted. Microbes and their metabolites serve as essential signals that educate and modulate immune responses. For instance, microbial-derived Short-Chain Fatty Acids (SCFAs) can promote regulatory T cell differentiation and suppress inflammation, contributing to immune tolerance. Conversely, the immune system shapes the composition of the microbiome through mechanisms such as antimicrobial peptides and immunoglobulins, which help maintain microbial balance and prevent pathogen colonization. The dysregulation of microbiome-immune interactions has been implicated in the pathogenesis of various diseases [3].

Inflammatory Bowel Diseases (IBD), such as Crohn's disease and ulcerative colitis, are characterized by dysbiosis and abnormal immune responses to gut microbes. Allergic disorders, such as asthma and eczema, have been associated with alterations in early-life microbial exposures and immune development. Autoimmune diseases, including rheumatoid arthritis and multiple sclerosis, are influenced by dysbiosis-driven immune dysregulation and molecular mimicry mechanisms. Understanding microbiome-immune interactions has spurred the development of innovative therapeutic approaches aimed at modulating microbial communities to improve health outcomes. Probiotics, live microorganisms with beneficial health effects, and prebiotics, dietary fibers that promote the growth of beneficial microbes, are used to restore microbial balance and enhance immune function. Synbiotics, combinations of probiotics and prebiotics, offer synergistic effects in promoting gut health. Fecal Microbiota Transplantation (FMT) has emerged as a potent therapy for recurrent Clostridioides difficile infections, demonstrating the therapeutic potential of microbiome manipulation in clinical settings [4].

Furthermore, ongoing research explores the use of microbial-based therapies and microbiome-targeted drugs to treat various diseases by leveraging the immunomodulatory properties of specific microbial taxa and their metabolites.This description provides an in-depth exploration of microbiome-immune interactions, emphasizing their impact on disease pathogenesis and highlighting therapeutic interventions aimed at leveraging these interactions for clinical benefit. Advances in microbiome research have illuminated the complex mechanisms governing microbiome-immune interactions and their profound implications for disease pathogenesis and therapy. Harnessing this knowledge holds promise for developing personalized strategies that modulate the microbiome to enhance immune health and mitigate disease risks. Future research endeavors aim to unravel the intricacies of microbiome-immune crosstalk, refine therapeutic interventions, and translate these findings into clinical practice to improve patient outcomes and quality of life [5].

Conclusion

The burgeoning field of microbiome-immune interactions represents a paradigm shift in our understanding of health and disease. The intricate interplay between the human microbiome and the immune system not only influences immune development, regulation, and responses but also plays a pivotal role in the pathogenesis of various diseases across different organ systems. Dysbiosis, characterized by alterations in microbiome composition and function, has been implicated in the onset and progression of numerous disorders, ranging from Inflammatory Bowel Diseases (IBD) and allergic conditions to autoimmune disorders, metabolic syndromes, and even neurological diseases. These conditions underscore the critical role of microbiome-immune crosstalk in maintaining physiological balance and homeostasis. The therapeutic implications of microbiome-immune interactions are profound. Advances in microbiome research have paved the way for innovative therapeutic strategies aimed at modulating microbial communities to promote health and mitigate disease risks. Probiotics, prebiotics, synbiotics, and Fecal Microbiota Transplantation (FMT) represent promising avenues for restoring microbial balance, enhancing immune function, and treating microbiome-related disorders. Moving forward, continued research efforts are needed to deepen our understanding of the mechanisms underlying microbiome-immune interactions and their impact on disease outcomes.

This includes elucidating specific microbial metabolites, pathways, and immune mechanisms that drive health or contribute to disease pathology. Such insights will be instrumental in developing targeted interventions that harness the microbiome's immunomodulatory potential for personalized medicine approaches. In conclusion, the integration of microbiome science into clinical practice holds immense promise for optimizing patient care and improving outcomes in diverse disease settings. By leveraging our understanding of microbiome-immune interactions, we can aspire to develop tailored therapies that enhance immune resilience, mitigate disease progression, and ultimately foster a healthier future for individuals worldwide. This conclusion summarizes the current understanding of microbiome-immune interactions, emphasizes their therapeutic potential, and calls for further research to unlock their full clinical utility in disease prevention and treatment.

Acknowledgment

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Alagawany, Mahmoud, Shaaban S. Elnesr, Mayada R. Farag and Mohamed E. Abd El-Hack, et al. "Potential role of important nutraceuticals in poultry performance and health-A comprehensive review." Res Vet Sci 137 (2021): 9-29.

Google Scholar, Crossref, Indexed at

2. Stęczny, Kamil and Dariusz Kokoszyński. "Effect of probiotic preparations (EM) on productive characteristics, carcass composition, and microbial contamination in a commercial broiler chicken farm." Anim Biotechnol 32 (2021): 758-765.

Google Scholar, Crossref, Indexed at

3. Yadav, Sudhir, Kayla D. Caliboso, Jannel E. Nanquil and Jiachao Zhang, et al. "Cecal microbiome profile of Hawaiian feral chickens and pasture-raised broiler (commercial) chickens determined using 16S rRNA amplicon sequencing." Poult Sci 100 (2021): 101181.

Google Scholar, Crossref, Indexed at

4. Dehau, Tessa, Richard Ducatelle, Filip Van Immerseel and Evy Goossens. "Omics technologies in poultry health and productivity-part 1:Current use in poultry research." Avian Pathol 51 (2022): 407-417.

Google Scholar, Crossref, Indexed at

5. Shang, Yue, Sanjay Kumar, Brian Oakley and Woo Kyun Kim. "Chicken gut microbiota: Importance and detection technology." Front Vet Sci 5 (2018): 254.

Google Scholar, Crossref, Indexed at